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Summary
Objective: To evaluate the in vivo chondroprotective effect of cyclodextrin polysulphate (CDPS) in a rabbit model of experimental osteoarthritis
(OA).
Design: Experimental OA was induced in rabbits by anterior cruciate ligament transection (ACLT). Forty-eight hours post-surgery, the rabbits
were randomised into three treatment groups (n¼ 15 in each group) and a sham-operated control group. The rabbits were either injected
subcutaneously with saline, 0.25 mg/kg CDPS or 1 mg/kg CDPS once a week for a period of 12 weeks, and their weight was monitored
as a parameter for their general status. The animals were then sacriﬁced for macroscopic and histological assessment of the knee joints.
Results: At the lowest dose, CDPS treatment was unable to induce a signiﬁcant improvement of cartilage degradation vs the saline control in
the experimentally induced knee OA. However, subcutaneous injections of 1 mg/kg CDPS induced a marked inhibition (P< 0.05) of osteo-
phyte formation. Additionally, a signiﬁcant reduction of cartilage degradation revealed an overall chondroprotective effect of CDPS at
a concentration of 1 mg/kg. No signiﬁcant effects on weight gain were noted.
Conclusions: Systemic administration of CDPS is able to protect cartilage in vivo and can therefore be considered as a chondroprotective
agent with structure modifying capacities.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Structural changes in the tissues of an osteoarthritic joint
will eventually lead to the loss of function and the subjective
complaints associated with this condition. To a limited ex-
tent, articular cartilage cells are capable of restoring carti-
lage damage, characteristic for the course of osteoarthritis
(OA). However, beyond a critical point cartilage repair by
chondrocytes becomes inadequate. The need to develop
agents that are capable of modifying the mechanisms
underlying this pathological condition remains an important
research objective.
In a ﬁrst attempt at improving the structure and function of
cartilage, precursors of extracellular matrix (ECM) compo-
nents i.e. glycosaminoglycans, were administered to re-
store the chondrocyte environment and prevent further
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986chondroitin sulphate (CS) was shown to increase aggrecan
synthesis by articular cartilage cells4 and both CS and
chondroitin polysulphate increased hyaluronan synthesis
by synovial lining cells in vitro5 and in vivo6. Similarly, hu-
man articular chondrocytes in monolayer culture responded
with an increased synthesis of highly polymerised hyalur-
onan when chondroitin polysulphate was supplemented to
the culture medium, showing a more ‘structure modifying’
capacity of these molecules7. Several placebo controlled
trials have shown that the effect of CS as a symptom mod-
ifying drug is somewhat controversial8,9. However, when
structural changes were considered, OA was less progres-
sive in the treatment group compared to the placebo con-
trols10e14. Therefore, one may conclude that there is
evidence for a mild to moderate effect due to CS.
Aside from CS, other sulphated polysaccharides have
been suggested as potential regulators of connective tissue
repair processes. Electron microscopic studies conﬁrmed
that xylosan polysulphate (XPS) is capable of stimulating
differentiated human cartilage cells to immobilise a higher
numbers of aggrecans on longer hyaluronan ﬁlaments in
vitro14. In vivo experiments have led to the conclusion that
the molecular weight of hyaluronan also increased in the
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neous airpouch15 and in the joint ﬂuid of human volunteers
who received intra-articular injections of this polysaccha-
ride16. Furthermore, the loss of proteoglycan (PG) from ar-
ticular cartilage in rabbit joints, destabilised by an anterior
cruciate ligament transection (ACLT), was reduced by intra-
muscular administrations of XPS17. In the Moskowitz rabbit
OA model, a signiﬁcant reduction in the histological scoring
was observed after an intra-articular injection with XPS18,19.
Considering their protective effect and capability of in-
creasing synthesis rates of physiologically important ECM
molecules, some of these sulphated polysaccharides have
been considered to be promising therapeutical tools in OA.
A major ﬂaw when these substances are introduced for
pharmacological use in humans is their poor chemical def-
inition. The exact molecular weight is varying. The degree
and type of sulphation is different on each of the individual
molecules. One class of biologically occurring polysaccha-
rides with a well-deﬁned molecular structure and weight
are the cyclodextrins. a-, b- and g-Cyclodextrins are cyclic
polysaccharides containing 6, 7 and 8 glucopyranose
units, respectively, linked through a 1,4-glycosidic bonds.
Classical sulphation procedures result in the sulphation
of the three free hydroxyl groups of the glucopyranoses.
An in vitro study on the inﬂuence of fully sulphated a-,
b- and g-cyclodextrins on the ECM metabolism of human
articular cartilage chondrocytes has revealed that all three
cyclodextrins equally and signiﬁcantly improved aggrecan
synthesis. Exposure to cyclodextrin polysulphate (CDPS)
further induced a down regulation of intracellular IL-1a
and -b and a concomitant increase in aggrecan, collagen
type II and ﬁbronectin in the cell associated matrix (CAM)
of human chondrocytes in alginate20. The amount of IL-6
released by CDPS-treated OA chondrocytes was de-
pressed by 60% compared to OA controls and equalled
the levels secreted by normal cells20. These data suggest
that CDPS positively affects the underlying pathology of
OA and this agent can therefore be classiﬁed as a struc-
ture or disease modifying OA drug (DMOAD).
This study analysed the chondroprotective characteristics
of CDPS in rabbits with knee OA induced by anterior cruci-
ate ligament transection (ACLT).Material and methodsPREPARATION OF SULPHATED CYCLODEXTRINSPyrogen-free g-CDPS was synthesised in the Institut de Recherche
SERVIER Laboratories (Orleans, France; Dr F. Lefoulon). Commercially
available cyclodextrin (Sigma Chemical Company, St. Louis, USA) was
sulphated according to the procedure described by Pitha et al.21 and Chen
et al.22. Elemental analysis, electrospray analysis and mass spectrometry
analysis were performed and conﬁrmed a degree of substitution from 20 to
24, the predominant being 22 sulphate. Considering an initial molecular
weight of 1297 Da for the unsulphated cyclodextrin, on sulphation of an
average of 22 free hydroxyl groups of the glucopyranoses its molecular
weight increased to 3055 Da.INDUCTION OF EXPERIMENTAL OASix months old, full grown mature, Fauve de Bourgogne male rabbits,
weighing 3.2e3.5 kg were used in these experiments. The animals were
kept in individual cages and were freely active. After an 8 day acclimatiza-
tion, these rabbits were divided into different treatment groups of 15 animals
each. A total of 60 animals were used, 15 of which were sham operated and
45 of which were submitted to an anterior cruciate ligament transection
(ACLT) of the right knee as described by Yoshioka et al.23. All animals
had surgery under sterile conditions using a general inhalational anaesthetic
(1% halothane and oxygen at 1 l/min). Brieﬂy, a medial parapatellar incision
was made through the skin and an arthrotomy performed. The patella was
dislocated laterally and the knee placed in full ﬂexion. The anterior cruciateligament (ACL) was visualised and transected. The joint was then irrigated
with sterile saline and closed. The capsule and the synovium were closed to-
gether. Postoperative treatment consisted of buprenorhine 0.01 mg/kg body
weight, two intramuscular injections daily for 2 days.
The right knee of the sham rabbits was opened, the patella dislocated, the
knee irrigated and closed, but the ACL was not cut.
Forty-eight hours post-surgery each groups of 15 rabbits was injected sub-
cutaneously either with saline, 0.25 mg/kg CDPS or 1 mg/kg CDPS once
a week for a period of 12 weeks. Sham rabbits also received a subcutaneous
injection with saline weekly. The animals were fed a standard diet with tap wa-
ter ad libitum. The weight of these rabbits was observed during the treatment
period to evaluate their general health. The animals were then euthanised
using an overdose of sodiumbarbital and the liver, kidneys, tibial plateau,
femoral condyles, trochlear groove and patella were subjected to a blinded,
macroscopic evaluation. The local animal committee approved the study.MACROSCOPIC EVALUATIONSScoring of the articular cartilage of the rabbit knee joints was based on
physician’s overall assessment using a 100-mm-length visual analogical
scale (VAS) system24. Representative gross morphological changes in car-
tilage at the femoral condyles, tibial plateau, patella and trochlear groove
were graded from 0 (no lesions) to 100 (exposure of subchondral bone).
Apart from this general score, the amount of osteophytes at the articular
surface was represented by a grade from 0 to 3, more speciﬁc 0 e non-
existent, 1 e small/disputable, 2 e evident and 3 e large.
The liver and kidneys from the animals were post-mortem examined for
lesions or haemorrhages.PROCESSING OF TISSUES FOR HISTOPATHOLOGY
AND HISTOCHEMISTRYSamples of femoral condyles and tibial plateaus were obtained and ﬁxed
immediately in 10% neutral buffered formalin. After ﬁxation, these tissues
were decalciﬁed with 14% ethylenediaminetetraacetic acid (EDTA) and em-
bedded in parafﬁn. Six micron tissue sections were taken from the same lo-
cation in a frontal plane through the centre of the tibial plateau and the
femoral condyles. A small piece of bone was left attached to the cartilage
for histological analysis. The samples were always taken from the same an-
atomic locations. The sections were stained with haematoxylin and eosin for
an analysis of the general morphology or with safranin-O for a relative as-
sessment of proteoglycan content.HISTOLOGICAL GRADING OF THE KNEE JOINTSTwo non-consecutive stained histological sections were analysed ‘blind’ in
code by two readers at a 10-fold magniﬁcation. The histological scores used
in this study are based on those introduced by Colombo et al.25 and modiﬁed
by Kikuchi et al.26. The following parameters were evaluated: osteophytes,
clones, denudation of bone, loss of superﬁcial layer, erosion of cartilage, ﬁbril-
lation and/or ﬁssures, loss of proteoglycan, disorganisation of chondrocytes,
loss of chondrocytes and cluster formation. Eight of these parameters evalu-
ate the cartilage while the scoring of osteophytes reﬂects the changes at the
bone/cartilage lining. This scoring system includes the most pertinent patholog-
ical changes in OA. Each item was graded from 0 to þ4, in detail 0 e no
changes from normal; þ1 e small, questionable lesions; þ2 e focal deﬁnite
lesions; þ3 e extensive pathologic lesions; þ4 e extreme pathologic
changes. Femoral condyles and tibial plateaus were scored by two indepen-
dent investigators using the guidelines suggested by Colombo et al.STATISTICAL ANALYSISChanges of weight over time were evaluated by mixed model analysis
with random intercepts and random slopes27. Histological scores were com-
pared between groups by means of 1-side exact ManneWhitney U tests.
Also, a composite score to evaluate cartilage degradation was constructed
based on sensitivity analysis, logistic regression and discriminant analysis,
taking into account the positive (ACLT rabbits) and negative controls
(sham-operated rabbits). Eventually the composite scores were compared
between groups by means of 1-side exact ManneWhitney U tests.ResultsGENERAL CONDITION AND BODY WEIGHT MEASUREMENT
OF THE ANIMALSPrior to the investigation of the chondroprotective effect
of CDPS in experimental OA, the general condition of the
Fig. 1. Weight gain of each treatment group over time. Fourteen rabbits underwent a sham surgery. A total of 41 rabbits underwent ACLT
surgery. Twelve rabbits were then treated with saline (ACLT), 14 with 0.25 mg/kg CDPS and 15 with 1 mg/kg CDPS. Values represent
mean 1 S.E.M.
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of weights over time revealed that there were no signiﬁcant
differences in weight gain between treated and ACLT
rabbits (Fig. 1). Sham-operated animals, in contrast, had
a signiﬁcant higher weight gain than ACLT rabbits
(P¼ 0.018). Furthermore, there were no rabbits that
showed toxicological signs during the treatment or post-
mortem.GROSS MORPHOLOGICAL ASSESSMENT OF THE KNEE
JOINTSKnee joints from 14 sham rabbits, 12 ACLT rabbits, 29
CDPS-treated animals (14 with the 0.25 mg/kg and 15
with the 1.0 mg/kg dose) were used for a morphological
analysis. On gross macroscopical examination all animals
appeared to spontaneously develop cartilage changes
and osteophytes in the medial knee compartments. The ex-
tent of the structural tissue changes in this area of the knees
was akin in all study groups. In the lateral knee compart-
ments, however, cartilage and osteophyte scores were
more divergent. In these compartments, the cartilage le-
sions of the CDPS-treated rabbits (for both the 0.25 mg/kg
and the 1 mg/kg dose) were reduced [Fig. 2(1)]. The
same tendency was observed for the osteophytes
[Fig. 2(2)]. However, the variability of these subjective
scores was too high for reliable statistical inference. No dif-
ference was found in the VAS scores for the trochlear
groove and patella between the different treatment groups.
This study aimed at ﬁnding out in how far progression of
the disease in these animals had been retarded by the
treatment. Therefore, only the lateral tibial plateau and the
femoral condyles were thus subject of more methodical his-
tological analysis. No further histological analysis was per-
formed on the other sites.HISTOLOGICAL GRADING TO EVALUATE OSTEOARTHRITIC
CHANGESConstruction of a composite index to evaluate
cartilage degradation
For the construction of the composite index we used the
positive (ACLT rabbits) and negative controls (sham rab-
bits). From the initial eight parameters that evaluatedcartilage degradation, two parameters (ﬁbrillation and/or ﬁs-
sures and clones) were eliminated due to the limited sensi-
tivity to change. From the remaining six variables,
multivariate analysis (logistic regression and discriminant
analysis) highlighted that the following variables (exposure
of bone, loss of chondrocytes, and loss of PG) did not pos-
itively contribute to the classifying model. The loadings of
the ﬁnal composite index were again determined by multi-
variate analysis and simpliﬁed. This ﬁnally resulted in the
following weight factors: 1.6 for disorganisation of chondro-
cytes, 1.3 for loss of superﬁcial layer and 1 for erosion of
cartilage.
Histological evaluation
Representative histological sections of sham operated,
ACLT and 1.0 mg/kg CDPS-treated ACLT rabbit tibial pla-
teaus are presented in Fig. 3. The mechanical stress on
the ACL transected knee joints signiﬁcantly modiﬁed
some of the considered parameters (Table I). The manifes-
tation of osteophytes on the articular surfaces, which was
already observed in the macroscopic assessment, was
the most obvious pathological change in this OA model
(P¼ 0.014). The remaining joint damage was especially
located at the superﬁcial layer (P¼ 0.012) and the concom-
itant loss and the disorganisation of chondrocytes (P¼
0.038 and 0.021, respectively). The signiﬁcant increase of
osteophyte formation by ACLT, could be inhibited by 60%
in the animals treated with 0.25 mg/kg CDPS, while the
1 mg/kg dose was able to cause a 100% inhibition
(P¼ 0.014) (Fig. 4). The 1 mg/kg CDPS-treated animals
also showed a recovery in the organisation of chondrocytes
at the superﬁcial layer, although this seemed not statisti-
cally signiﬁcant (P¼ 0.053). Furthermore, the scores for
cartilage erosion and exposure of bone in the 1 mg/kg
CDPS-treated joints tend to indicate a repair of the dam-
aged cartilage (Table I).
Twelve weeks after surgery, the difference between the
composite score of the pathological group and the animals
treated with 0.25 mg/kg was not signiﬁcant, this dose, how-
ever, tends to ameliorate the evaluated parameters as
a whole. The effect of the 1 mg/kg CDPS treatment was
more substantial, as the composite score proved to be sig-
niﬁcantly lower (P¼ 0.023) in this treatment group than in
the saline group (Fig. 5).
Fig. 2. (1) A: Mean macroscopic VAS score of medial femoral condyles and tibial plateaus of sham rabbits (SH, n¼ 14), ACLT rabbits treated
with saline (ACLT) (n¼ 12), 0.25 mg/kg CDPS (n¼ 14) or 1 mg/kg CDPS (n¼ 15). B: Mean macroscopic VAS score of lateral femoral con-
dyles and tibial plateaus of the four treatment groups. Bars represent mean 1 S.E.M. (2) A: Severity of osteophytes at the medial tibial pla-
teaus and femoral condyles of sham-treated rabbits (SH) and rabbits that underwent ACLT treated with saline (ACLT), 0.25 mg/kg CDPS or
1 mg/kg CDPS. B: Variation in osteophyte severity at the lateral tibial plateaus and femoral condyles of the four treatment groups. Bars rep-
resent mean scores of tibial plateaus and femoral condyles 1 S.E.M.
Fig. 3. Safranin-O staining of a representative marginal area of a tibial plateau of a (A) sham-operated control, (B) ACLT knee with ﬁbrillated
cartilage surface, loss of superﬁcial safranin-O staining (*), and obvious osteophyte formation (**), (C) 1.00 mg/kg CDPS-treated ACLT rabbit
showing small osteophyte (**), and (D) 0.25 mg/kg CDPS-treated ACLT rabbit with cartilage ulceration on the central part of the lateral half of
the tibial plateau (*). Original magniﬁcation 25.
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Table I
Statistics of histological scores for each treatment group
Loss of
superﬁcial layer
Cartilage
erosion
Fibrillation/
ﬁssures
Loss of
proteoglycan
Disorganisation
of chond.
Loss of
chond.
Exposure sub-
chondral bone
Formation
of clones
Osteophytes Score
Sham Mean 1.50 1.57 1.00 1.46 1.36 1.57 1.50 1.00 1.54 5.69
Median 1.25 1.50 1.00 1.50 1.00 1.50 1.50 1.00 1.50 5.43
IQR 1.00 1.00 0.00 1.00 1.00 1.00 1.00 0.00 1.00 2.54
SD 0.65 0.55 0.00 0.50 0.46 0.58 0.52 0.00 0.41 1.57
P-value 0.012 0.073 0.371 0.334 0.021 0.038 0.106 0.149 0.014 0.006
ACLT Mean 2.42 1.92 1.04 1.71 1.92 2.00 1.92 1.25 2.13 8.13
Median 2.25 2.00 1.00 1.50 2.00 2.00 1.75 1.00 2.00 7.98
IQR 1.88 0.38 0.00 1.00 0.50 0.38 1.38 0.38 0.38 3.04
SD 1.08 0.56 0.14 0.89 0.76 0.71 0.82 0.50 0.80 2.59
P-value Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
CDPS
0.25 mg/
kg
Mean 2.43 1.60 1.00 1.47 1.83 1.83 1.50 1.00 1.77 7.70
Median 2.50 2.00 1.00 1.00 2.00 2.00 1.00 1.00 2.00 7.95
IQR 2.00 1.00 0.00 1.00 0.50 0.50 1.00 0.00 0.50 2.10
SD 1.116 0.47 0.00 0.55 0.36 0.41 0.68 0.00 0.42 1.45
P-value 0.500 0.092 0.360 0.307 0.472 0.434 0.084 0.139 0.118 0.415
CDPS
1.00 mg/
kg
Mean 1.96 1.57 1.00 1.82 1.46 1.71 1.43 1.00 1.56 6.47
Median 2.00 1.50 1.00 1.75 1.50 2.00 1.00 1.00 1.50 6.58
IQR 1.63 1.00 0.00 0.75 1.00 0.50 1.00 0.00 1.00 2.68
SD 0.82 0.47 0.00 0.67 0.46 0.38 0.55 0.00 0.41 1.39
P-value 0.149 0.059 0.371 0.247 0.053 0.174 0.059 0.149 0.014 0.023
Differences between groups for each parameter and the overall composite score were analysed by a 1-side exact ManneWhitney U test
with the ACLT group as a reference (ref.). IQR¼ inter quartile range; SD¼ standard deviation.
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Present pharmacotherapy in OA is limited by the focus
on pain relief and the lack of structure modifying activities.
A recent study, using alginate cultured chondrocytes,
which maintain the phenotype and the metabolic charac-
teristics of the chondrocytes isolated from OA cartilage,
showed that CDPS improved the synthesis of aggrecan
and the accumulation of CAM macromolecules. The
mechanism by which these anabolic activities are induced,
may involve a repression of the IL-1 pathway as the intra-
cellular IL-1a and -b concentration of CDPS-treated OA
chondrocytes was decreased20. The capacity of IL-1 to
stimulate chondrocytes to produce most proteinases in-
volved in cartilage destruction has been established28e31.
IL-1 is also capable of inducing the expression of other
cytokines among which IL-632e34. It is therefore that the
signiﬁcantly decreased release of IL-6 by CDPS-treated
chondrocytes in the cell culture supernatant20 can be
seen as an indirect reduction of the IL-1 concentration.
The anti-catabolic effect of CDPS on in vitro cultured
chondrocytes points out that it has an effect on the under-
lying pathological conditions seen in OA. Further examina-
tion in vivo can show the usefulness of this agent as a
DMOAD.
The present study examined the effect of this CDPS on
experimental OA in rabbits. In the most widely used and
studied model of OA, the anterior cruciate ligament is trans-
ected to induce joint instability, as mechanical instability is
believed to be the initiating factor for onset and progression
of cartilage degeneration in human OA.
A preliminary dose-ﬁnding experiment with a subcutane-
ous administration of 1 mg/kg, 5 mg/kg and 30 mg/kg
CDPS, three times a week, was performed earlier. In the
group that received the highest dose, nephrogenic haemor-
rhages led to the death of some animals. Other animals
displayed lesions in kidneys and liver. Polysulphatedcyclodextrins have been shown to posses important biolog-
ical activities similar to those of heparin35e38. These data
conﬁrm an anti-coagulant characteristic of CDPS at high
concentrations. Internal organs from rabbits treated with
1 mg/kg, however, did not show any hemorrhagic or other
gross changes in the macroscopical anatomy.
Furthermore, the ACLT procedure and the developing ar-
ticular dysfunction and pain may have affected the animals’
general condition, which gave reason to the decrease in
weight gain of these ACLT animals. The fact that there is
no signiﬁcant weight difference between the ACLT-treated
rabbits and the CDPS-treated animals, shows that CDPS
has no additional effect on the general health.
Evidently, more detailed investigations on systemic side
effects will be mandatory before CDPS would enter any
clinical phase of its development as a drug.
When the gross morphological changes at the articular
surface were evaluated, it was obvious that the cartilage
scores and the formation of osteophytes, induced by the
ACLT, diminished as a consequence of therapy. At ﬁrst
glance, both 0.25 mg and 1.00 mg CDPS per kilogram
body weight regimens appeared effective. However, the
changes in these macroscopic observations were not
statistically signiﬁcant and at most suggested some chon-
droprotective effects of CDPS, which were most obvious
in the lateral compartments of the rabbit knee. The histo-
morphometric studies therefore concentrated on these
compartments of the rabbit joints.
In the literature, the changes following ACLT are de-
scribed as ﬁbrillation and erosion of the articular surface,
early loss of proteoglycan, increased cellularity, disorgani-
sation of chondrocytes, exposure of subchondral bone and
osteophytes39. Although OA involves all joint tissues, carti-
lage changes have been taken as study objective in this
pilot study. These cartilage changes are summarised in
a histological scoring system established by Colombo et al.
Fig. 5. Histopathologic composite scores evaluated in the four
groups of animals. Results are presented as individual data points,
and the median for each group is indicated by the horizontal bar.
*P< 0.05 vs ACLT by a 1-side exact ManneWhitney U test.
Fig. 4. Histological evaluation of osteophytes at the femoral
condyles and the tibial plateau of sham-treated animals and rabbits
that underwent ACLT treated with saline (ACLT), 0.25 mg/kg CDPS
or 1 mg/kg CDPS. Bars represent mean 1 S.E.M.
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a whole, a composite score based on the scoring system
of Colombo et al. was constructed for this study. Therefore,
the effect of an ACLT procedure on the eight different pa-
rameters describing the cartilage, was compared to the ef-
fect of a sham treatment. Different validated histological
evaluations such as PG depletion40e42 did not contribute
in the ﬁnal composite index, which can be explained by cor-
relations between variables and by to the so-called curse of
multidimensionality indicating that a classiﬁer performs
worse when more variables are incorporated43. The com-
posite score we constructed, is valid for this particular rabbit
OA model, one should, however, be cautious to extrapolate
this score to other animal models.
The composite score of animals subcutaneously injected
with 0.25 mg/kg CDPS revealed no signiﬁcant cartilage
changes in comparison to the saline-treated rabbits. The
major chondroprotective effect, however, was clearly dem-
onstrated by treating the animals with 1 mg/kg CDPS. The
osteophytes analysed on the histological sections de-
creased signiﬁcantly. A comparable amelioration, repre-
sented by a signiﬁcantly decreased histological composite
score, was achieved at the cartilage site. The effect was
most marked at the cartilage surface, where less lesions
were observed and the superﬁcial layer seemed more con-
served. In addition, the organisation of chondrocytes was
re-established after a 1 mg/kg CDPS therapy.This study proves the ability of CDPS to inhibit cartilage
damage by restoring the homeostasis of chondrocytes in
vivo. As for the possible biomechanism of the CDPS-in-
duced chondroprotective effect in this ACL transection OA
model, we assume that CDPS reached sufﬁcient cartilage
tissue concentrations to inhibit the local tumor necrosis fac-
tor (TNF)-a-induced auto/paracrine IL-1 activities. Mechan-
ical abuse of chondrocytes has been shown to activate
NFkB, a key transcription factor controlling the transcription
of many inﬂammatory genes, to cause increased mRNA
levels of proinﬂammatory IL-1 and TNF-a and programmed
cell death in cultured chondrocytes44,45. These ﬁndings
concur with the observation of apoptosis in articular carti-
lage under mechanical stress46. It can be expected that
pharmacologically effective concentrations of CDPS
reached the cartilage. The afﬁnity and the tendency of poly-
sulphated polyssacharides to accumulate in articular carti-
lages have been emphasised for chondroitin polysulphate.
Serum levels and concentrations in the synovium of pa-
tients with OA after i.m. administration of 50 mg of chondroi-
tin polysulphate were 0.55 mg and 0.11 mg/ml after 3 h and
24 h, respectively. However, the concentrations in cartilage
24 h following the same dosage amounted to 1.45 mg/g
which corresponded approximately to three times the serum
levels 3 h after administration47. Of note is the previous ﬁnd-
ing that 2.5 mg of CDPS per millilitre of culture medium sig-
niﬁcantly affected chondrocyte anabolic activity in vitro20.
The protective effect of CDPS on cartilage in vivo has
been clearly demonstrated by a decreased progression of
OA in this rabbit model.
992 S. Groeneboer et al.: CDPS protects articular cartilageIn conclusion, CDPS can be considered as a chondropro-
tective, structure modifying OA drug, which offers novel
approaches in the treatment of patients with OA.Conﬂict of interest
G. Verbruggen has licenced cyclodextrin polysulphate for
therapeutical use in degenerative joint disease.References
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